disitamab vedotin   Click here for help

GtoPdb Ligand ID: 13716

Synonyms: Aidixi® | RC-48 | RC48-ADC
Approved drug
disitamab vedotin is an approved drug
Compound class: Antibody
Comment: Disitamab vedotin (RC48) is an anti-epidermal growth factor receptor 2 (ERBB2; HER2) antibody-drug conjugate (ADC) [4]. Its cytotoxic payload is the potent antimitotic agent monomethyl auristatin E (MMAE). Antibody binding blocks ERBB2 signalling and intracellular release of MMAE inhibits microtubule formation and induces apoptosis. The antibody may also mediate antibody-dependent cell-mediated cytotoxicity (ADCC).
References
1. Deeks ED. (2021)
Disitamab Vedotin: First Approval.
Drugs, 81 (16): 1929-1935. [PMID:34661865]
2. Jiang J, Li S, Shan X, Wang L, Ma J, Huang M, Dong L, Chen F. (2020)
Preclinical safety profile of disitamab vedotin：a novel anti-HER2 antibody conjugated with MMAE.
Toxicol Lett, 324: 30-37. [PMID:31877330]
3. Sheng X, Wang L, He Z, Shi Y, Luo H, Han W, Yao X, Shi B, Liu J, Hu C et al.. (2024)
Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2-Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials.
J Clin Oncol, 42 (12): 1391-1402. [PMID:37988648]
4. Shi F, Liu Y, Zhou X, Shen P, Xue R, Zhang M. (2022)
Disitamab vedotin: a novel antibody-drug conjugates for cancer therapy.
Drug Deliv, 29 (1): 1335-1344. [PMID:35506447]